

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

IMMTECH INTERNATIONAL INC
Form 10-Q
February 14, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 for the quarterly period ended December 31, 2002.

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 for the transition period from
_____ to _____.

Commission File Number: 000-25669

IMMTECH INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

39-1523370

(State or other jurisdiction of
incorporation or organization)

(I. R. S. Employer
Identification No.)

150 Fairway Drive, Suite 150, Vernon Hills, Illinois 60061

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number: (847) 573-0033

Indicate by checkmark whether the registrant: (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act. Yes No

As of January 31, 2003, 7,661,310 shares of the Registrant's common stock, par
value \$0.01 ("Common Stock"), were outstanding.

INDEX

Page No.

PART I. FINANCIAL INFORMATION.....	1
Item 1. Condensed Financial Statements.....	1
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.....	15

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

Item 3. Quantitative and Qualitative Disclosures about Market Risk.....20
Item 4. Controls and Procedures.....20

PART II. OTHER INFORMATION.....21

Item 1. Legal Proceedings.....21
Item 2. Changes in Securities and Use of Proceeds.....21
Item 3. Defaults Upon Senior Securities.....23
Item 4. Submission of Matters to a Vote of Security Holders.....23
Item 5. Other Information.....24
Item 6. Exhibits, and Reports on Form 8-K.....24

Exhibit Index.....25

SIGNATURES.....26

-i-

PART I. FINANCIAL INFORMATION

Item 1. Condensed Financial Statements.

IMMTECH INTERNATIONAL, INC.
(A Development Stage Enterprise)

CONDENSED BALANCE SHEETS (UNAUDITED)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents
Restricted funds on deposit
Other current assets

Total current assets

PROPERTY AND EQUIPMENT - Net

OTHER ASSETS

TOTAL

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable
Accrued expenses
Deferred revenue

Total current liabilities

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

DEFERRED RENTAL OBLIGATION

Total liabilities

STOCKHOLDERS' EQUITY:

Preferred stock, par value \$0.01 per share, 4,440,000 shares authorized and unissued
 Series A convertible preferred stock, par value \$0.01 per share, stated value \$25 per share, 320,000 shares authorized, 142,800 and 160,100 shares outstanding as of December 31, 2002 and March 31, 2002, respectively; aggregate liquidation preference of 3,633,287 as of December 31, 2002
 Series B convertible preferred stock, par value \$0.01 per share, stated value \$25 per share, 240,000 shares authorized, 76,725 shares outstanding as of December 31, 2002; aggregate liquidation preference of \$1,950,075 as of December 31, 2002
 Common stock, par value \$0.01 per share, 30,000,000 shares authorized, 6,395,647 and 6,066,459 shares issued and outstanding as of December 31, 2002 and March 31, 2002, respectively
 Additional paid-in capital
 Deficit accumulated during the developmental stage

Total stockholders' equity

TOTAL

See notes to condensed financial statements.

2

IMMTECH INTERNATIONAL, INC.
 (A DEVELOPMENT STAGE ENTERPRISE)

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)

	THREE MONTHS ENDED DECEMBER 31,		NINE MO DEC
	2002	2001	2002
REVENUES	\$ 233,830	\$ 954,660	\$ 1,024,082
EXPENSES:			
Research and development	401,667	1,205,808	1,864,193
General and administrative	723,978	689,328	3,059,166
Equity in loss of joint venture			
Total expenses	1,125,645	1,895,136	4,923,359

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

LOSS FROM OPERATIONS	(891,815)	(940,476)	(3,899,277)
OTHER INCOME (EXPENSE):			
Interest income	3,130	2,409	13,031
Interest expense			
Loss on sales of investment securities - net			
Cancelled offering costs			
Other income (expense) - net	3,130	2,409	13,031
LOSS BEFORE EXTRAORDINARY ITEM	(888,685)	(938,067)	(3,886,246)
EXTRAORDINARY GAIN ON EXTINGUISHMENT OF DEBT			
NET LOSS	(888,685)	(938,067)	(3,886,246)
CONVERTIBLE PREFERRED STOCK DIVIDENDS	(96,249)		(362,996)
REDEEMABLE PREFERRED STOCK CONVERSION, PREMIUM AMORTIZATION AND DIVIDENDS			
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	\$ (984,934)	\$ (938,067)	\$ (4,249,242)
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS:			
Net loss	\$ (0.14)	\$ (0.16)	\$ (0.62)
Convertible preferred stock dividends	(0.02)		(0.06)
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	\$ (0.16)	\$ (0.16)	\$ (0.68)
WEIGHTED AVERAGE SHARES USED IN COMPUTING BASIC AND DILUTED LOSS PER SHARE	6,350,855	6,055,371	6,246,023

See notes to condensed financial statements.

3

IMMTECH INTERNATIONAL, INC.
(A DEVELOPMENT STAGE ENTERPRISE)

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

THREE MONTHS ENDED
DECEMBER 31,

2002

2001

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

OPERATING ACTIVITIES:

Net loss	\$ (888,685)	\$ (938,067)	\$ (3,886)
Adjustments to reconcile net loss to net cash used in operating activities:			
Compensation recorded related to issuance of common stock, common stock options and warrants	55,963	85,087	1,132
Depreciation and amortization of property and equipment	23,654	25,480	71
Deferred rental obligation	(1,591)	(1,592)	(4)
Equity in loss of joint venture			
Loss on sales of investment securities - net			
Amortization of debt discounts and issuance costs			
Extraordinary gain on extinguishment of debt			
Changes in assets and liabilities:			
Restricted funds on deposit	(1,843,265)	751,339	(2,534)
Other current assets	(35,000)	50,000	4
Other assets			
Accounts payable	(5,047)	419,092	(201)
Accrued expenses	(6)		(3)
Deferred revenue	1,817,170	(858,215)	2,575
	-----	-----	-----

Net cash used in operating activities	(876,807)	(466,876)	(2,846)
	-----	-----	-----

INVESTING ACTIVITIES:

Purchases of investment securities			
Proceeds from sales and maturities of investment securities			
Purchases of property and equipment	(5,397)		(1)
Investment in and advances to joint venture			
	-----	-----	-----

Net cash used in investing activities	(5,397)		(16)
	-----	-----	-----

FINANCING ACTIVITIES:

Advances from stockholders and affiliates			
Proceeds from issuance of notes payable			
Principal payments on notes payable			
Payments for debt issuance costs			
Payments for extinguishment of debt			
Proceeds from issuance of redeemable preferred stock			
Net proceeds from issuance of common stock			
Net proceeds from issuance of convertible preferred stock and warrants	25,000		1,859
Payments for convertible preferred stock dividends and for fractional shares of common stock resulting from the conversions of convertible preferred stock	(86)		
Additional capital contributed by stockholders			
	-----	-----	-----

Net cash provided by financing activities	24,914		1,859
	-----	-----	-----

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(857,290)	(466,876)	(1,003)
--	-----------	-----------	---------

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	1,892,029	530,770	2,037
	-----	-----	-----

CASH AND CASH EQUIVALENTS, END OF PERIOD	\$ 1,034,739	\$ 63,894	\$ 1,034
	=====	=====	=====

See notes to condensed financial statements.

IMMTECH INTERNATIONAL, INC.
(A DEVELOPMENT STAGE ENTERPRISE)

NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

1. BASIS OF PRESENTATION

The accompanying condensed financial statements have been prepared by Immtech International, Inc. (the "Company") pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and, in the opinion of the Company, include all adjustments necessary for a fair statement of results for each period shown (unless otherwise noted herein, all adjustments are of a normal recurring nature). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such SEC rules and regulations. The Company believes that the disclosures made are adequate to prevent the financial information given from being misleading. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company's latest Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q.

2. COMPANY BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business - Immtech International, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of drugs to treat infectious diseases that include fungal infections, malaria, tuberculosis, hepatitis C, Pneumocystis carinii pneumonia and tropical medicine diseases including African sleeping sickness (Trypanosomiasis) and Leishmaniasis. The Company is a development stage enterprise and since its inception on October 15, 1984, the Company has engaged in research and development programs, expanding its network of scientists and scientific advisors, technology licensing agreements, and advancing its technology platform toward commercialization. The Company uses the expertise and resources of strategic partners and contracted parties in a number of areas, including: (i) laboratory research, (ii) pre-clinical and human clinical trials and (iii) the manufacture of pharmaceutical products. The Company holds worldwide patents, licenses and rights to license worldwide patents, patent applications and technologies from third parties that are integral to the Company's business. The Company has licensing and commercialization rights to a dicationic anti-infective pharmaceutical platform and is developing drugs intended for commercial use based on that platform.

The Company does not have any products currently available for sale, and no products are expected to be commercially available for sale prior to the 4th calendar quarter of 2003 if at all.

Going Concern Presentation and Related Risks and Uncertainties - The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

Since inception, the Company has incurred accumulated losses of approximately \$42,355,000. Management expects the Company to continue to

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

incur significant losses during the next several years as the Company continues its research, development and commercialization activities and clinical trial efforts. There can be no assurance that the Company's continued research will lead to the development of commercially viable products. The Company's operations to date have consumed substantial amounts of cash. Negative cash flow from operations is expected to continue in the foreseeable future. The Company will require substantial funds to conduct research and

5

development, laboratory and clinical testing and to manufacture (or have manufactured) and market (or have marketed) its product candidates.

The Company's working capital is not sufficient to fund the Company's operations through the commercialization of one or more products yielding sufficient revenues to support the Company's operations; therefore, the Company will need to raise additional funds. The Company believes its existing unrestricted cash and cash equivalents and the grants the Company has received or has been awarded and is awaiting disbursement of, will be sufficient to meet the Company's planned expenditures through May 2003, although there can be no assurance the Company will not require additional funds. These factors, among others, indicate that the Company may be unable to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The Company's ability to continue as a going concern is dependent upon its ability to generate sufficient funds to meet its obligations as they become due and, ultimately, to obtain profitable operations. Management's plans for the forthcoming year, in addition to normal operations, include continuing their efforts to obtain additional equity and/or debt financing, obtain additional research grants and enter into various research and development agreements with other entities.

Cash and Cash Equivalents - The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist of an amount on deposit at a bank and an investment in a money market mutual fund, stated at cost, which approximates fair value.

Restricted Funds on Deposit - Restricted funds on deposit consist of cash on deposit at a bank which is restricted for use in accordance with a clinical research subcontract agreement with The University of North Carolina at Chapel Hill.

Investment - The Company accounts for its investment in NextEra Therapeutics, Inc. ("NextEra") on the equity method. As of December 31, 2002 and March 31, 2002, the Company owned approximately 28% of the issued and outstanding shares of NextEra common stock. The Company has recognized an equity loss in NextEra to the extent of the basis of its investment, and the investment balance is zero as of December 31, 2002 and March 31, 2002. Recognition of any investment income on the equity method by the Company for its investment in NextEra will occur only after NextEra has earnings in excess of previously unrecognized equity losses.

Income Taxes - The Company accounts for income taxes using an asset and liability approach. Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. In addition, the valuation allowance is recognized if it is more likely than not that some or all of the deferred income tax assets will not be realized. A valuation allowance is used to offset the related net deferred income tax assets due to uncertainties of realizing the benefits of certain net operating loss and tax credit carryforwards and other deferred income tax assets.

Net Income (Loss) Per Share - Net income (loss) per share is calculated in accordance with Statement of Financial Accounting Standards No. 128, "Earnings Per Share." Basic net income (loss) per share and diluted net loss per share are computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net income per share, when applicable, is computed by dividing net income attributable to common stockholders by

6

the weighted average number of common shares outstanding increased by the number of potential dilutive common shares based on the treasury stock method. Diluted net loss per share was the same as the basic net loss per share for the three and nine months ended December 31, 2002 and 2001, as the Company's outstanding common stock options, warrants and conversion features of Series A and B Convertible Preferred Stock were antidilutive.

Comprehensive Loss - There were no differences between comprehensive loss and net loss for the three and nine month periods ended December 31, 2002 and 2001, respectively.

New Accounting Standards - In December 2002, the FASB issued Statement of Financial Accounting Standards ("SFAS") No. 148, "Accounting for Stock-Based Compensation-Transition and Disclosure." SFAS No. 148 amends SFAS No. 123, "Accounting for Stock-Based Compensation," to provide alternative methods of transition to SFAS No.123's fair value method for accounting for stock-based employee compensation. SFAS No. 148 also amends the disclosure provisions of SFAS No. 123 and Accounting Principles Board ("APB") Opinion No. 28, "Interim Financial Reporting," to require disclosure in the summary of significant accounting policies of the effects of an entity's accounting policy with respect to stock-based employee compensation on reported net income and earnings per share in annual and interim financial statements. The Company is in the process of assessing the impact of SFAS No. 148 and will adopt this standard for periods beginning after December 15, 2002.

3. STOCKHOLDERS' EQUITY

Series A Convertible Preferred Stock - On February 14, 2002, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware designating 320,000 shares of the Company's 5,000,000 authorized shares of preferred stock as Series A Convertible Preferred Stock, \$0.01 par value, with a stated value of \$25.00 per share. Dividends accrue at a rate of 6.0% per annum on the \$25.00 stated value per share and are payable semi-annually on April 15 and October 15 of each year while the shares are outstanding. The Company has the option to pay the dividend either in cash or in equivalent shares of common stock, as defined. Accrued preferred stock dividends are included in the carrying value of the Series A Convertible Preferred Stock in the accompanying condensed balance sheets. Each share of Series A Convertible Preferred Stock shall be convertible by the holder at any time into shares of the Company's common stock at a

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

conversion rate determined by dividing the \$25.00 stated value, plus any accrued and unpaid dividends (the "Liquidation Price"), by a \$4.42 conversion price (the "Conversion Price"), subject to certain antidilution adjustments as defined in the Certificate of Designation. On April 15, 2002 and October 15, 2002 the Company issued 8,249 and 28,959 shares of common stock and paid \$165.92 and \$64.23 to holders of fractional shares as dividends on the Series A preferred shares, respectively. During the three month period ended December 31, 2002, certain Series A preferred stockholder converted 8,000 shares of Series A Convertible Preferred Stock and the related dividend for 45,978 shares of common stock. A total of \$56,127 was accrued for the preferred stock dividend payable April 15, 2003 and was reported in the net loss attributable to common stockholder in the accompanying statement of operations for the three months ended December 31, 2002. During the nine month period ended December 31, 2002, certain Series A preferred stockholders converted 17,300 shares of Series A Convertible Preferred Stock including accrued dividends for 99,105 shares of common stock.

The Company may at any time after February 14, 2003, require that any or all outstanding shares of Series A Convertible Preferred Stock be converted into shares of the Company's common stock, provided that the shares of common stock into which the Series A Convertible Preferred Stock are convertible are registered pursuant to an effective registration statement, as defined. The number of

7

shares of common stock to be received by the holders of the Series A Convertible Preferred Stock upon conversion at the request of the Company shall be determined by (i) dividing the Liquidation Price by the Conversion Price provided that the closing bid price for the Company's common stock exceeds \$9.00 for 20 consecutive trading days within 180 days prior to notice of conversions, as defined, (ii) or if the requirements of (i) are not met, the number of shares of common stock is determined by dividing 110% of the Liquidation Price by the Conversion Price. The Conversion Price is subject to certain antidilution adjustments, as defined in the Certificate of Designation.

The Company may at any time, upon 30 day notice, redeem any or all outstanding shares of the Series A Convertible Preferred Stock by payment of the Liquidation Price to the holder of such shares, provided that the holder does not convert the Series A Convertible Preferred Stock into shares of Common Stock during the 30 day period. The Series A Convertible Preferred Stock has a preference in liquidation equal to \$25.00 per share, plus any accrued and unpaid dividends. Each issued and outstanding share of Series A Convertible Preferred Stock is entitled to 5.6561 votes (subject to adjustment for dilution) with respect to any and all matters presented to the stockholders of the Company for their action or consideration. Except as provided by law or by the provisions establishing any other series of preferred stock, Series A Convertible Preferred stockholders and holders of any other outstanding preferred stock shall vote together with the holders of common stock as a single class.

Series B Convertible Preferred Stock - On September 25, 2002, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware designating 240,000 shares of the Company's 5,000,000 authorized shares of preferred stock as Series B Convertible Preferred Stock, \$0.01 par value, with a stated value of \$25.00 per share. Dividends accrue at a rate of 8.0% per annum on the \$25.00 stated value per share and

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

are payable semi-annually on April 15 and October 15 of each year while the shares are outstanding. The Company has the option to pay the dividend either in cash or in equivalent shares of common stock, as defined. Accrued preferred stock dividends are included in the carrying value of the Series B Convertible Preferred Stock in the accompanying condensed balance sheets. Each share of Series B Convertible Preferred Stock shall be convertible by the holder at any time into shares of the Company's common stock at a conversion rate determined by dividing the \$25.00 stated value, plus any accrued and unpaid dividends (the "Liquidation Price"), by a \$4.00 conversion price (the "Conversion Price"), subject to certain antidilution adjustments, as defined in the Certificate of Designation. During September 2002 the Company issued 75,725 shares of preferred stock, Series B Convertible Preferred for net proceeds of \$1,834,333 (net of offering costs of \$58,900 of which \$18,700 was paid during the quarter-ended June 30, 2002). During the quarter ended December 31, 2002 the Company issued 1000 shares of preferred stock, Series B Convertible Preferred for net proceeds of \$25,000. On October 15, 2002, the Company issued 2,658 shares of common stock and paid \$16.59 to holders of fractional shares as dividends on the Series B preferred shares. A total of \$38,173 was accrued for the preferred stock dividend payable April 15, 2003 and was reported in the net loss attributable to common stockholder in the accompanying statement of operations for the three months ended December 31, 2002.

The Company may at any time after September 24, 2003, require that any or all outstanding shares of Series B Convertible Preferred Stock be converted into shares of the Company's common stock, provided that the shares of common stock into which the Series B Convertible Preferred Stock are convertible are registered pursuant to an effective registration statement, as defined. The number of shares of common stock to be received by the holders of the Series B Convertible Preferred Stock upon conversion at the request of the Company shall be determined by (i) dividing the Liquidation Price by the Conversion Price provided that the closing bid price for the Company's common stock exceeds \$9.00 for 20 consecutive trading days within 180 days prior to notice of conversions, as defined, (ii) or if the requirements of (i) are not met, the number of shares of common stock is

8

determined by dividing 110% of the Liquidation Price by the Conversion Price. The Conversion Price is subject to certain antidilution adjustments, as defined in the Certificate of Designation.

The Company may at any time, upon 30 day notice, redeem any or all outstanding shares of the Series B Convertible Preferred Stock by payment of the Liquidation Price to the holder of such shares, provided that the holder does not convert the Series B Convertible Preferred Stock into shares of Common Stock during the 30 day period. The Series B Convertible Preferred Stock has a preference in liquidation equal to \$25.00 per share, plus any accrued and unpaid dividends. Each issued and outstanding share of Series B Convertible Preferred Stock shall be entitled to 6.25 votes (subject to adjustment for dilution) with respect to any and all matters presented to the stockholders of the Company for their action or consideration. Except as provided by law or by the provisions establishing any other series of preferred stock, Series B Convertible Preferred stockholders and holders of any other outstanding preferred stock shall vote together with the holders of common stock as a single class.

In September 2002 and October 2002, the Company, in connection with the Series B Convertible Preferred Stock private placement offerings, issued warrants to purchase 189,312 and 2,500 shares of the Company's common stock

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

at an exercise price of \$6.125 per share of common stock, respectively. The warrants expire at various dates in September and October 2007. At any time after the first anniversary of the date of grant and if the Company's common stock closes above 200% of the exercise price for 20 consecutive trading days, the Company may, upon 20 days notice, redeem any unexercised portion of any warrants for a redemption fee of \$.10 per share of common stock underlying the warrants. During the 20 day notice period, if the warrants are then exercisable as a result of the conversion or redemption of the Series B Convertible Preferred Stock, such warrant holder may then exercise all or a portion of the warrant by tendering the appropriate exercise price.

The warrants issued in September 2002 to the holders of the Series B Preferred Convertible Stock were valued using the Black-Scholes option valuation model and the amount recorded of \$147,483 was determined by applying the relative fair value method in relation to the estimated fair value of Series B Convertible Preferred Stock resulting in a \$147,483 preferred stock dividend calculated in accordance with the Emerging Issues Task Force ("EITF") Issue No. 00-27, "Application of Issue No. 98-5 to Certain Convertible Instruments." The dividend on the Series B Convertible Preferred Stock was charged to deficit accumulated during the development stage immediately upon issuance, as the preferred stock is immediately convertible. The preferred stock dividend of approximately \$149,000 and the accrued preferred stock dividends of approximately \$40,700 were reported as dividends in determining the net loss attributable to common stockholders in the accompanying statement of operations for the nine months ended December 31, 2002.

Common Stock - On June 28, 2002, the Company entered into a Finder's Agreement with an individual to develop and qualify potential strategic partners for the purpose of testing and/or the commercialization of Company products in China. As consideration for entering into the agreement, the individual received 150,000 shares of the Company's common stock and the Company recognized approximately \$757,500 as a general and administrative expense during the three month period ended September 30, 2002, based on the estimated fair value of the shares issued.

On July 31, 2002, the Company entered into a one year agreement with The Gabriele Group, L.L.C. ("Gabriele") for assistance to be provided by Gabriele to the Company with respect to management consulting, strategic planning, public relations and promotions. As compensation for these services, the company granted Gabriele 40,000 shares of the Company's common stock and the Company recognized approximately \$187,600 as a general and administrative expense during the three month

9

period ended September 30, 2002, based on the estimated fair value of the shares issued. The Company also granted Gabriele warrants to purchase 30,000 shares of the Company's common stock at \$6.00 per share. These warrants vest when the price of the Company's common stock reaches certain milestones, beginning at \$10.00 per share for a period of 20 consecutive days. This agreement may be renewed for additional one year terms at the sole discretion of the Company.

Common Stock Options - On October 12, 2000, the Company's board approved the issuance of options to purchase shares of common stock to certain employees and other nonemployees who have been engaged to assist the Company in various research and administrative capacities as part of the 2000 Stock Incentive Plan. The 2000 Stock Incentive Plan provides for the

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

issuance of up to 350,000 shares of common stock, in the form of incentive options and non-qualified stock options. At the stockholders meeting held November 15, 2002, the stockholders approved an amendment to the 2000 Stock Incentive Plan to increase the number of shares of common stock reserved for issuance from 350,000 shares to 1,100,000 shares. Options granted under the 2000 Stock Incentive Plan that expire without exercise are available to be reissued. The incentive stock options must be granted at a price at least equal to fair market value on the date of grant.

The Company has granted common stock options to individuals who have contributed to the Company in various capacities. The options contain various provisions regarding vesting periods and expiration dates. The options generally vest over periods ranging from 0 to 4 years and generally expire after five or ten years. During the three and nine month periods ended December 31, 2002, the Company issued 203,000 options to purchase shares, of common stock to its employees and directors. During the three and nine month periods ended December 31, 2002, 0 and 20,000 options expired, respectively, which were previously granted under the 2000 Stock Incentive Plan which are available to be reissued. As of December 31, 2002, there were 620,750 shares available for grant (including 12,000 shares which are reserved for issuance under certain consulting agreements with nonemployees).

During the three and nine months ended December 31, 2002, the Company issued options to purchase 0 and 22,000 shares, respectively, of common stock to nonemployees and recognized expense of approximately \$56,000 and \$187,000, respectively, related to these options and certain options issued prior to July 1, 2002 which vest over a four year service period. During the three months ended December 31, 2001, the Company did not issue any options to nonemployees and recognized expense of approximately \$85,000 related to certain options issued prior to July 1, 2001 which vest over four year service periods. During the nine months ended December 31, 2001, the Company issued options to purchase 12,000 shares of common stock to nonemployees and recognized expense of approximately \$247,000 related to these options and certain options issued prior to July 1, 2001 which vest over four year service periods. The expenses were determined based on the estimated fair value of the options issued.

The Company's stockholders exercised options for 0 and 217 shares of common stock during the three and nine months ended December 31, 2002.

4. COLLABORATIVE RESEARCH AND DEVELOPMENT ACTIVITIES

The Company has various collaborative research agreements with commercial enterprises. Under the terms of these arrangements, the Company has agreed to perform best efforts research and development and, in exchange, the Company may receive advanced cash funding and may also earn additional fees for the attainment of certain milestones. The Company may receive royalties on the sales of such products. The other parties generally receive exclusive marketing and distribution rights for certain products for set time periods in specific geographic areas.

The Company initially acquired its rights to the platform technology and indications developed by a consortium of universities consisting of The University of North Carolina at Chapel Hill ("UNC"), Duke University, Auburn University and Georgia State University (the "Consortium") pursuant to an agreement, dated January 15, 1997 (as amended, the "Consortium Agreement") among the Company, Pharm-Eco Laboratories, Inc. ("Pharm-Eco"),

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

and UNC (to which each of the other members of the Consortium agreed shortly thereafter to become a party). The Consortium Agreement commits the parties to collectively research, develop, finance the research and development of, manufacture and market both the technology and compounds owned by the Consortium and previously licensed or optioned to Pharm-Eco (the "Current Compounds") and to license to the Company in accordance with the Consortium Agreement, all technology and compounds developed by the Consortium after January 15, 1997, through use of Company-sponsored research funding or National Cooperative Drug Development grant funding made available to the Consortium (the "Future Compounds" and, collectively with the Current Compounds, the "Compounds").

The Consortium Agreement contemplated that upon the completion of the Company's initial public offering ("IPO") of shares of its common stock with gross proceeds of at least \$10,000,000 by April 30, 1999, the Company and Pharm-Eco, with respect to the Current Compounds, and the Company and UNC, (on behalf of the Consortium), with respect to Future Compounds, would enter into license agreements for, or assignments of, the intellectual property rights relating to the Compounds held by Pharm-Eco and the Consortium; pursuant to which the Company would pay royalties and other payments based on revenues received for the sale of products based on the Compounds.

The Company completed its IPO on April 26, 1999, with gross proceeds in excess of \$10,000,000. Pursuant to the Consortium Agreement, both Pharm-Eco and the Consortium then became obligated to grant or assign to the Company an exclusive worldwide license to use, manufacture, have manufactured, promote, sell, distribute, or otherwise dispose of any products based directly or indirectly on all of the Current Compounds and Future Compounds.

As a result of the closing of the IPO, the Company issued an aggregate of 611,250 shares of common stock, of which 162,500 shares were issued to the Consortium and 448,750 shares were issued to Pharm-Eco or persons designated by Pharm-Eco.

Pursuant to the Consortium Agreement, the Company may, subject to the satisfaction of certain conditions, be required to issue 100,000 shares of common stock to the Consortium upon the filing by the Company of the first new drug application or an abbreviated new drug application with the Food and Drug Administration with respect to a product incorporating certain Compounds. In addition, the Company will pay the Consortium an aggregate royalty of up to 5.0% of net sales derived from the Compounds, except that the royalty rate payable on any Compound developed at Duke University will be determined by negotiation at the time such Compound is developed. In the event that the Company sublicenses its rights with respect to the Compounds to a third party, the Company will pay the Consortium a royalty based on a percentage of any royalties the Company receives, and a percentage of all signing, milestone and other payments made to the Company pursuant to the sublicense agreement.

As contemplated by the Consortium Agreement, on January 28, 2002, the Company entered into a License Agreement with the Consortium whereby the Company received the exclusive license to commercialize dication technology and compounds developed or invented by one or more of the Consortium scientists after January 15, 1997, and which also incorporated into such License Agreement the Company's existing license with the Consortium with regard to the Current Compounds.

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

In June 1999, the Company entered into a research and manufacturing agreement with Pharm-Eco for Pharm-Eco to produce good manufacturing practices quality, as defined, dicationic drugs and products for clinical testing and for early commercialization. Pharm-Eco was unable to manufacture certain required compounds and the Company subsequently engaged alternate suppliers who successfully manufactured the compounds.

In August 2000, Pharm-Eco and two of its senior executives filed suit in Delaware against the Company in connection with a dispute under the Consortium Agreement. The Company responded by denying the allegations and filing a counter-claim against Pharm-Eco for breach of contract.

The Company filed a Motion for Summary Judgment, which was granted on February 21, 2001. In his Memorandum Opinion, the Vice Chancellor hearing the proceeding dismissed all of the plaintiffs' claims against the Company and held that Pharm-Eco had breached the Consortium Agreement by failing to grant or assign to the Company a license for the Current Compounds. On March 12, 2001, the Vice Chancellor signed a Final Order and Judgment directing Pharm-Eco to execute and deliver to the Company an agreement granting or assigning to the Company the license. On March 27, 2001, Pharm-Eco and the Company entered into an agreement assigning the license. No further claims against the Company remain in this proceeding, and on May 1, 2001, a Stipulation of Dismissal was filed with the Court.

On April 20, 2001, the Company entered into a settlement agreement with Pharm-Eco and certain other parties resolving all remaining matters between them. Pursuant to this agreement, the Company received a cash payment of \$1,000,000; an assignment from Pharm-Eco of various contract rights; and a termination of all of the Company's obligations to Pharm-Eco, including, without limitation, (a) the obligation to issue an aggregate of 850,000 warrants for shares of the Company's stock, (b) the obligation to issue shares of common stock upon the occurrence of a certain future event, (c) the obligation to pay a percentage of all non-royalty payments that the Company might receive under any sublicense that the Company might enter into with respect to certain compounds, and (d) certain accounts payable which Pharm-Eco claimed to be owed of approximately \$159,000; and a release of any and all claims that Pharm-Eco may have had against the Company. The cash payment received and the accounts payable obligations which were forgiven, aggregating approximately \$1,159,000, was recorded as a credit to (reduction of) research and development expense during the three months ended June 30, 2001; as the Company had previously expensed the estimated fair value of the shares of common stock issued to Pharm-Eco at the time of the IPO and the accounts payable obligations, as research and development expense.

The Company was required, under an agreement which has subsequently expired, to make quarterly research grants in the amount of \$100,000 to UNC through April 30, 2002. During the three month period ended December 31, 2001, the Company expensed grant payments to UNC of \$100,000. During the nine month periods ended December 31, 2002 and 2001, the Company expensed grant payments to UNC of \$100,000 and \$300,000, respectively. Such payments were recorded as research and development costs.

In August 2000, the Company was awarded two Small Business Innovation Research ("SBIR") grants aggregating approximately \$831,000 from the National Institutes of Health ("NIH") to research various infections. During the three and nine months ended December 31, 2001, the Company recognized revenues of approximately \$65,000 and \$503,000, respectively, from these grants. During the three and nine months ended December 31, 2001, the Company expensed payments of approximately \$86,000 and \$189,000, respectively, to UNC and certain other Consortium universities for contracted research related to these grants. There is no additional funding

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

available to the Company under these grants.

12

In August 2001, the Company was awarded an additional SBIR grant from the NIH of approximately \$144,000 as the third year grant to continue research on "Novel Procedures for Treatment of Opportunistic Infections." During the three and nine months ended December 31, 2002, the Company recognized revenues of approximately \$0 and \$70,000, respectively, from this grant and expensed payments of approximately \$0 and \$70,000, respectively, to UNC and certain other Consortium universities for contracted research related to this grant. There is no additional funding available to the Company under this grant.

During the three month periods ended December 31, 2002 and 2001, the Company expensed approximately \$99,000 and \$58,000, respectively, of other payments to UNC and certain other Consortium universities for patent related costs and other contracted research. Total payments expensed to UNC and certain other Consortium universities were approximately \$99,000 and \$222,000 during the three months ended December 31, 2002 and 2001, respectively. During the nine months ended December 31, 2002 and 2001 the Company expensed approximately \$231,000 and \$231,000, respectively, of other payments to UNC and certain other Consortium universities for reimbursement of patent related costs and other contracted research. Total payments expensed to UNC and certain other Consortium universities were approximately \$401,000 and \$727,000 during the nine months ended December 31, 2002 and 2001, respectively. Included in accounts payable as of December 31, 2002 and March 31, 2002, were approximately \$66,000 and \$267,000, respectively, due to UNC and certain other Consortium universities.

In November 2000, The Bill & Melinda Gates Foundation ("Gates Foundation") awarded a \$15,114,000 grant to UNC to develop new drugs to treat Human Trypanosomiasis (African sleeping sickness) and Leishmaniasis. On March 29, 2001, UNC entered into a clinical research subcontract agreement with the Company, whereby the Company is to receive up to \$9,800,000, subject to certain terms and conditions, over a five year period to conduct certain clinical and research studies. The proceeds from this agreement are restricted and must be segregated from the Company's other funds and used for specific purposes. On March 29, 2001, the Company received a first installment of \$4,300,000, on September 24, 2002 approximately \$1,364,000 and on December 31, 2002 approximately \$2,016,000 of which approximately \$199,000 and \$804,000 was utilized for clinical and research purposes conducted and expensed during the three months and nine months ended December 31, 2002. The Company has recognized aggregate revenues since inception of approximately \$4,541,000 through December 31, 2002 for services performed under the agreement, including approximately \$199,000 and \$804,000 during the three and nine months ended December 31, 2002. The remaining amount (approximately \$3,139,000 as of December 31, 2002) has been deferred and will be recognized as revenue over the term of the agreement as the services are performed.

On April 22, 2002, the Company entered into a Confidentiality, Testing and Option Agreement with Neurochem, Inc., ("Neurochem"), a Canadian corporation, to supply Neurochem with selected dicationic compounds for the testing, evaluation and potential future licensing of such compounds for (i) the treatment and diagnosis of amyloidosis and the related underlying conditions of Alzheimer's Disease, cerebral amyloid angiopathy, primary amyloidosis, diabetes, rheumatic diseases and (ii) the treatments of conditions related to secondary amyloidosis. Neurochem has the right to

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

license tested compounds upon the conclusion of the Confidentiality, Testing and Option Agreement, as defined in the agreement. The Company has recognized revenues for the three and nine month period ended December 31, 2002 of \$35,000 and \$150,000, respectively.

13

5. SUBSEQUENT EVENTS

On January 13, 2003, the Company issued 1,200,000 shares of its common stock pursuant to a joint venture entered into with an investor ("seller") who owned 100% of the outstanding equity of Lenton Fibre Optics Development Limited ("Lenton"), a Hong Kong company. The primary purpose of the joint venture is to construct and operate a pharmaceutical manufacturing facility capable of producing commercial quantities of the Company's pharmaceutical products at competitive costs. The land is located in a "free-trade zone" called the Futian Free Trade Zone, Shenzhen, in the Peoples Republic of China. The Company intends, once the facility is built and government approvals are obtained, to engage the joint venture company to manufacture for commercial distribution, Immtech's pharmaceutical products intended for sale in Asia, Africa and other selected regions. Under the terms of the agreement, the joint venture will be operated under the name Immtech Hong Kong Limited.

The Company purchased an 80% interest in Lenton from the seller pursuant to a Share Purchase Agreement relating to Shares in Lenton Fibre Optics Development Limited for the aggregate consideration of 1,200,000 unregistered shares of Immtech common stock. The unaudited pro forma condensed balance sheet below reflects the historical financial position of the Company, with pro forma adjustments as if the joint venture had closed on December 31, 2002. The accounting for the joint venture reflects the preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on their estimated fair values.

	DECEMBER 31, 2002
ASSETS	
Total current assets	\$ 4,119,608
Property and equipment - net	120,054
Other assets:	
Investment	2,856,000
Deposits	19,848

Total assets	\$7,115,510 =====
LIABILITIES AND STOCKHOLDERS' EQUITY	
Total current liabilities	\$3,533,157
Deferred rental obligation	22,371

Total liabilities	3,555,528

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

Total stockholders' equity	3,559,982 -----
Total liabilities and stockholders' equity	\$7,115,510 =====

As consideration for investment advisory services performed for the Company in connection with the acquisition of Lenton, two entities (Pacific Dragons Group Limited and Champion Traders Investment Limited) each received 30,000 shares of the Company's common stock.

14

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Forward-looking Statements

Certain statements contained in this report and in the documents incorporated by reference herein, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements frequently, but not always, use the words "intends," "plans," "believes," "anticipates" or "expects" or similar words and may include statements concerning the Company's strategies, goals and plans. Forward-looking statements involve a number of significant risks and uncertainties that could cause our actual results or achievements or other events to differ materially from those reflected in such forward-looking statements. Such factors include, among others described in this report and in our annual report, the following (i) we are in an early stage of product development, (ii) our technology is in the research and development stage and therefore its potential benefits for human therapy are unproven, (iii) the possibility that favorable relationships with collaborators cannot be established or, if established, will be abandoned by the collaborators before completion of product development, (iv) the possibility that we or our collaborators will not successfully develop any marketable products, (v) the possibility that advances by competitors will cause our product candidates not to be viable, (vi) uncertainties as to the requirement that a drug product be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if commenced and completed, will not establish the safety or efficacy of our drug product candidates, (vii) risks relating to requirements for approvals by governmental agencies, such as the FDA, before products can be marketed and the possibility that such approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to market our product candidates successfully, (viii) the risk that our patents could be invalidated or narrowed in scope by judicial actions or that our technology could infringe upon the patent or other intellectual property rights of third parties, (ix) the possibility that we will not be able to raise adequate capital to fund our operations through the process of developing and testing a successful product or that future financing will be completed on unfavorable terms, (x) the possibility that any products successfully developed by us will not achieve market acceptance and (xi) other risks and uncertainties which may not be described herein.

Overview

We are a pharmaceutical company focused on the development and commercialization of oral drugs to treat infectious diseases that include fungal

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

infections, malaria, tuberculosis, hepatitis C, Pneumocystis carinii pneumonia and tropical medicine diseases including African sleeping sickness (Trypanosomiasis) and Leishmaniasis. We hold worldwide patents, licenses and rights to license worldwide patents, patent applications, technologies from a scientific consortium and exclusive rights to commercialize products from those patents and licenses that are integral to our business.

15

Since our formation in October 1984, we have engaged in research and development programs, expanding our network of scientists and scientific advisors, licensing technology agreements, and advancing the commercialization of the dication technology platform. We use the expertise and resources of strategic partners and contracted parties in a number of areas, including: (i) laboratory research, (ii) pre-clinical and human clinical trials and (iii) manufacture of pharmaceutical products. We have licensing and exclusive commercialization rights to a dicationic anti-infective pharmaceutical platform and are developing drugs intended for commercial use based on that platform. These dication pharmaceuticals work by blocking life-sustaining enzymes from binding to the key sites in the "minor groove" of an organism's deoxyribonucleic acid ("DNA"), thereby killing the infectious organisms that cause fungal, parasitic, bacterial and viral diseases. The minor groove or key site on an organism's DNA is an area where enzymes interact with the DNA as part of their normal life cycle. Structurally, dications are chemical molecules that have two positively charged ends held together by a chemical linker. The composition of the dications, with positive charges on both ends (shaped like molecular barbells) allows dications to bind (similar to a bandaid) to the negatively charged active sites (sites where enzymes interact with DNA) of an infectious microorganism's DNA. The bound dications block the enzymes necessary to the life of the microorganism from attaching to certain of its DNA's active sites thereby killing the infectious microorganism.

Dication technology is the result of a research program developed by scientists at The University of North Carolina at Chapel Hill ("UNC"), Duke University ("Duke University"), Auburn University ("Auburn University") and Georgia State University ("Georgia State") (collectively, the "Consortium"). We entered into an agreement with the Consortium, dated January 15, 1997, as amended, and a License Agreement, dated as of January 28, 2002 (collectively, the "Consortium Agreements"), to commercialize product candidates resulting from the Consortium's research, including the dication technology.

We have entered Phase IIb human trials with our lead compound DB289 for treatment of African sleeping sickness (Trypanosomiasis) and expect, assuming results consistent with our prior trials, to book orders for sales of DB289 for limited distribution in certain African countries by the end of calendar year 2003 or first quarter 2004. In connection with the above limited distribution product orders, we anticipate using our existing, and engaging new, pharmaceutical manufacturers to produce the quantities of DB289 needed, and seeking foreign regulatory approvals to import the product into the selected countries, all of which may take several months or more to complete. We have also entered into a joint venture arrangement with a Hong Kong entity whereby we acquired real property located in a "free trade zone" in the Peoples Republic of China on which we intend, through the joint venture entity Immtech Hong Kong Limited, to construct a pharmaceutical manufacturing facility to produce our future products.

Results of Operations

Immtech has not generated any revenue from operations and does not anticipate generating any revenue from operations prior to the 4th calendar

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

quarter of 2003. The Company has funded, and plans to continue to fund, its operations through research funding agreements and grants, and the sale of debt and equity securities. For the period from inception, October 15,

16

1984, to December 31, 2002, the Company incurred cumulative net losses of approximately \$42,355,000. The Company has incurred additional losses since such date and expects to incur additional operating losses for the foreseeable future.

Three Months Ended December 31, 2002 Compared with the Three Months Ended December 31, 2001.

Revenues under collaborative research and development agreements were approximately \$234,000 and \$955,000 for the three months ended December 31, 2002 and December 31, 2001, respectively. For the three months ended December 31, 2002 there were revenues recognized of approximately \$199,000 relating to a clinical research subcontract agreement between the Company and UNC and revenues of \$35,000 relating to the Confidentiality, Testing and Option Agreement between the Company and Neurochem, Inc. ("Neurochem"), while for the three months ended December 31, 2001, there were revenues recognized of approximately \$858,000 relating to the clinical research subcontract agreement between the Company and UNC and grant revenues of approximately \$97,000 from SBIR grants from the NIH. The clinical research subcontract agreement relates to a grant from the Bill & Melinda Gates Foundation ("Gates Foundation") to UNC to develop new drugs to treat Trypanosomiasis (African sleeping sickness) and Leishmaniasis. This program was initiated in March 2001. Grant and research and development agreement revenue is recognized as research is completed under the terms of the respective agreements, according to Company estimates. Grant and research and development funds received prior to completion under the terms of the respective agreements are recorded as deferred revenues.

Interest income for the three months ended December 31, 2002 was approximately \$3,000. Interest income for the three months ended December 31, 2001 was approximately \$2,000. The increase is due to an increase in available funds invested. The Company had no interest expense for the three months ended December 31, 2002 and December 31, 2001.

Research and development expenses decreased to approximately \$402,000 in the three months ended December 31, 2002 from approximately \$1,206,000 in the three months ended December 31, 2001. The Company had significant expenses relating to pre-clinical studies required for regulatory filings and purchase of product in the three months ended December 31, 2001 that were not incurred in 2002.

General and administrative expenses increased for the three months ended December 31, 2002 to approximately \$724,000 from approximately \$689,000 for the three months ended December 31, 2001.

We incurred a net loss of approximately \$889,000 for the three months ended December 31, 2002 as compared with a net loss of approximately \$938,000 for the three months ended December 31, 2001.

Nine Months Ended December 31, 2002 Compared with the Nine Months ended December 31, 2001.

17

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

Revenues under collaborative research and development agreements were approximately \$1,024,000 and \$2,914,000 for the nine months ended December 31, 2002 and 2001, respectively. For the nine months ended December 31, 2002 there were revenues recognized of approximately \$804,000 relating to the clinical research subcontract agreement between the Company and UNC, grant revenues of approximately \$70,000 from SBIR grants from the NIH and revenues of \$150,000 relating to the Confidentiality, Testing and Option Agreement between the Company and Neurochem, while for the nine months ended December 31, 2001, there were revenues recognized of approximately \$2,379,000 relating to the clinical research subcontract agreement between the Company and UNC and grant revenues of approximately \$535,000 from SBIR grants from the NIH.

Interest income for the nine months ended December 31, 2002 was approximately \$13,000. Interest income for the nine months ended December 31, 2001 was approximately \$39,000. The decrease is due to a reduction in funds invested and a reduction in interest rates paid on the invested funds. The Company had no interest expense for the nine months ended December 31, 2002 and December 31, 2001.

Research and development expenses decreased to approximately \$1,864,000 in the nine months ended December 31, 2002 from approximately \$2,987,000 in the nine months ended December 31, 2001. The decrease for the period is primarily attributable to a reduction in expenses relating to pre-clinical studies required for regulatory filings and funding of clinical trials in the nine months ended December 31, 2001 that were not incurred in 2002.

General and administrative expenses increased for the nine months ended December 31, 2002 to approximately \$3,059,000 from approximately \$2,370,000 for the nine months ended December 31, 2001. The increase was primarily due to non-cash compensation charges of approximately \$946,000 recorded in the nine months ended December 31, 2002 related to the issuance of 150,000 shares of the Company's Common Stock to Mr. Cheung Ming Tak (for services with respect to introduction to strategic partners in China) and 40,000 shares of Common Stock to the Gabriele Group (for providing management consulting, strategic planning, public relations and promotions assistance). Additionally, the Company incurred increases of approximately \$86,000 in patent related expenses and approximately \$107,000 in travel expenses related to fund raising, offset by a decrease of approximately \$444,000 in legal fees.

We incurred a net loss of approximately \$3,886,000 for the nine months ended December 31, 2002 as compared with a net loss of approximately \$2,404,000 for the nine months ended December 31, 2001.

Liquidity and Capital Resources

As of December 31, 2002, the Company had approximately \$1,035,000 of cash and cash equivalents, substantially all of which were invested in a money market mutual fund.

There were equipment expenditures of approximately \$5,000 for the three month period ended December 31, 2001 as compared to no equipment expenditures for the same period last year. During the nine month periods ended December 31, 2002 and December 31, 2001,

equipment purchases were approximately \$16,000 and \$62,000, respectively. No significant purchases of equipment are anticipated by the Company.

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

The Company periodically receives cash from the exercise of common stock options. During the three months ended December 31, 2002 there were no options exercised and during the nine months ended December 31, 2002 there were 217 options exercised.

On September 25, 2002 and October 28, 2002 we closed private placements of 76,725 shares of our Series B Convertible Preferred Stock, \$0.01 par value ("Series B Stock"), pursuant to Regulation D and Regulation S of the Securities Act of 1933, as amended ("Securities Act") at a stated value of \$25.00 per share and warrants to purchase 191,813 shares of our Common Stock at an exercise price of \$6.125 per share of Common Stock for \$1,918,125 in the aggregate, before issue cost. Each share of Series B Stock, among other things, (i) earns an 8% dividend payable, at the Company's discretion, in cash or Common Stock, (ii) has a \$25.00 (plus accrued but unpaid dividends) liquidation preference pari passu with our Series A Convertible Preferred Stock, (iii) is convertible into 6.25 shares of Common Stock and (iv) may be redeemable by the Company after one year from issuance. The warrants expire five years from the date of grant and contain certain anti-dilution protections. A complete description of the designations, preferences, voting powers, qualifications, special or relative rights and privileges of the Series B Stock is contained in the Company's Series B Convertible Preferred Stock Certificate of Designation filed on a Current Report on Form 8-K on September 25, 2002. We believe our existing unrestricted cash and cash equivalents and the grants we have received or have been awarded and are awaiting disbursement of, will be sufficient to meet our planned expenditures through May 2003, although there can be no assurance we will not require additional funds.

To date, we have financed our operations with:

- o proceeds from the above mentioned Series B Stock private placements which in the aggregate raised net proceeds of approximately \$1,859,000;
- o proceeds from various other private placements of debt and equity securities, an initial public offering, exercises of stock options and warrants and other cash contributed from stockholders, which in the aggregate raised approximately \$26,896,000;
- o funding from research agreements, foundation grants, SBIR grants and Small Business Technology Transfer Program grants and testing agreements of approximately \$8,258,000; and
- o the use of stock, options and warrants in lieu of cash compensation.

Our cash resources have been used to finance, develop and begin commercialization of drug product candidates, including sponsored research, conduct of human clinical trials, capital expenditures, expenses associated with development of product candidates pursuant to an agreement, dated January 15, 1997, (the "Consortium Agreement"), among the Company, UNC, and Pharm-Eco Laboratories, Inc. (to which each of Duke University, Auburn University and

Georgia State agreed shortly thereafter to become a party, and all of which, collectively with UNC, are referred to as the "Consortium") and, as contemplated by the Consortium Agreement, under a license agreement dated January 28, 2002 ("Consortium License Agreement") with the Consortium, and general and administrative expenses. Over the next several years we expect to incur substantial additional research and development costs, including costs related to research in pre-clinical (laboratory) and human clinical trials,

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

administrative expenses to support our research and development operations and marketing expenses to launch the sale of any commercialized product that may be developed.

Our future working capital requirements will depend upon numerous factors, including the progress of research, development and commercialization programs (which may vary as product candidates are added or abandoned), pre-clinical testing and human clinical trials, achievement of regulatory milestones, third party collaborators fulfilling their obligations to the Company, the timing and cost of seeking regulatory approvals, the level of resources that the Company devotes to the engagement or development of manufacturing capabilities, the ability of the Company to maintain existing and to establish new collaborative arrangements with others to provide funding to the Company to support these activities, and other factors. In any event, we will require substantial funds in addition to our existing working capital to develop product candidates and otherwise to meet our business objectives.

Our ability to continue as a going concern is dependent upon our ability to generate sufficient funds to meet obligations as they become due and, ultimately, to obtain profitable operations. Management's plans for the remainder of the fiscal year, in addition to normal operations, include continuing their efforts to obtain additional financing and grants, and to enter into various research, development and commercialization agreements with other entities.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The Company's cash and cash equivalents are maintained primarily in U.S. dollar accounts and amounts payable for research and development to research organizations are contracted in U.S. dollars. Accordingly, the Company's exposure to foreign currency risk is limited because its transactions are primarily based in U.S. dollars. The Company does not have any other exposure to market risk. The Company will develop policies and procedures to manage market risk in the future as circumstances require.

Item 4. Controls and Procedures

The Company maintains "disclosure controls and procedures", as such term is defined under Exchange Act Rule 13a-14(c), that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. The Company has carried out an evaluation, within the 90 days prior to the date of filing of this report, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and Chief Financial

20

Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective in ensuring that material information relating to the Company, is made known to the Chief Executive Officer and Chief Financial Officer during the period in which this report was being prepared. There have been no significant changes in the Company's internal controls or in other factors that could significantly affect these controls subsequent to the date the Company completed its evaluation.

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

Dale M. Geiss v. Immtech International, Inc. and Criticare Systems, Inc.

On September 19, 2002 the Court (Circuit Court of the Nineteenth Judicial Circuit, Lake County, Illinois) granted Immtech's motion to dismiss plaintiff's amended complaint, but gave plaintiff another opportunity to file and serve an amended complaint, if he so chooses. Plaintiff filed a second amended complaint dated November 1, 2002 against the Company and Criticare alleging the same allegations as before. On December 6, 2002, the Company and Criticare again filed motions to dismiss plaintiff's amended complaint. On February 6, 2003, the Court denied the motions to dismiss and granted Criticare and Immtech 30 days to answer or otherwise plead to the Second Amended Complaint. The Company intends to vigorously defend against the allegations and believes the claims have no merit.

Except as noted above, in Part I, Item 3, Legal Proceedings, of the Form 10-K filed on July 15, 2002, in Part II, Item 1 of the Form 10-Q filed on November 14, 2002 and in Part II, Item 1 of the Form 10-Q filed on August 14, 2004, the Company is not aware of any pending litigation.

Item 2. Changes in Securities and Use of Proceeds.

Common Stock.

On January 13, 2003, the Company issued 1,200,000 shares of its Common Stock pursuant to a joint venture entered with an investor ("seller") who owned 100% of the outstanding equity of Lenton Fibre Optics Development Limited ("Lenton"), a Hong Kong company. The primary purpose of the joint venture is to construct and operate a pharmaceutical manufacturing facility capable of producing commercial quantities of the Company's pharmaceutical products at competitive costs. The land is located in a "free-trade zone" called the Futian Free Trade Zone, Shenzhen, in the Peoples Republic of China. The Company intends, once the facility is built and government approvals are obtained, to engage the joint venture company to manufacture for commercial distribution, Immtech's pharmaceutical products intended for sale in Asia, Africa and other selected regions. Under the terms of the agreement, the joint venture will be operated under the name Immtech Hong Kong Limited.

21

The Company purchased 80% of the outstanding equity of Lenton from the seller pursuant to a Share Purchase Agreement relating to Shares in Lenton Fibre Optics Development Limited dated January 13, 2003 by and among the seller, Lenton and the Company for the aggregate consideration of 1,200,000 unregistered shares of Common Stock. The Common Stock was issued to the seller pursuant to an exemption from registration under Regulation S of the Securities Act. The parties have also entered into a Shareholders' Agreement relating to Lenton Fibre Optics Development Limited dated January 13, 2003 that sets forth the parties agreement as to the affairs of the joint venture and the conduct of its business. The seller has guaranteed the obligations of Lenton under a Deed of Indemnity dated January 13, 2003. In connection with the structuring of the joint venture, the Company issued 30,000 shares of Common Stock to each of Pacific Dragons Group Limited and Champion Traders Investment Limited as compensation for their services.

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

On January 14, 2003 the Company filed a Current Report on Form 8-K attaching the Share Purchase Agreement as related to shares in Lenton Fibre Optics Development Limited, the Shareholders' Agreement relating to Lenton Fibre Optics Development Limited and the seller's Deed of Indemnity.

Issuance of Series B Stock

On October 28, 2002 we issued 1,000 shares of our Series B Stock pursuant to an exemption from registration under Regulation D of the Securities Act at a stated value of \$25.00 per share and warrants to purchase 2,500 shares of our Common Stock at an exercise price of \$6.125 per share of Common Stock for \$25,000 in the aggregate. Each share of Series B Stock, among other things, (i) earns an 8% dividend, (ii) has a \$25.00 (plus accrued but unpaid dividends) liquidation preference pari passu with our Series A Convertible Preferred Stock, (iii) is convertible into 6.25 shares of Common Stock and (iv) may be redeemable by the Company after one year from issuance. The warrants expire five years from the date of grant and contain certain anti-dilution protections. A complete description of the designations, preferences, voting powers, qualifications, special or relative rights and privileges of the Series B Stock is contained in the Company's Series B Convertible Preferred Stock Certificate of Designation filed on a Current Report on Form 8-K on September 25, 2002.

Option Exercise.

None.

Conversion of Series A Stock to Common Stock.

On December 20, 2002, the holders of Series A Convertible Preferred Stock ("Series A Stock") converted 8,000 shares of Series A Stock and accrued dividends into 45,978 shares of Common Stock.

Series A and Series B Stock Dividend Payment.

On October 15, 2002, the Company issued 31,617 shares of Common Stock in the aggregate as preferred stock dividends to the holders of outstanding shares of Series A Stock and Series B Stock, pro rata based on the number of the shares of Series A Stock and Series B Stock

22

held. On January 8, 2003 the Company discovered a miscalculation in the dividend due certain holders of Series A Stock and issued an additional 5,663 shares of Common Stock in the aggregate to those holders.

Use of Proceeds.

Immtech will use proceeds from the sale of its stock, including the exercise of options and warrants, for general corporate purposes.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders.

VOTES OF THE SHAREHOLDERS.

The Company held its Annual Meeting on November 15, 2002 at the Westin

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

O'Hare in Rosemont, Illinois. The following matters were presented to the stockholders: (1) election of five directors to serve until the next annual meeting of the stockholders, (2) Proposal 1 - approval of an amendment to the Company's 2000 Stock Incentive Plan to increase the number of shares of Common Stock reserved for issuance thereunder from 350,000 shares to 1,100,000 shares, (3) Proposal 2 - approval of the conversion of Series A Stock held by certain officers and directors of the Company into Common Stock and (4) Proposal 3 - ratification of the Company's Board of Director's selection of Deloitte & Touche LLP as the Company's independent auditors for the fiscal year ending March 31, 2003. The results of the votes are as follows:

The following individuals were elected Directors by the Shareholders

	VOTES FOR
T. Stephen Thompson	4,762,046
Harvey M. Colten, M.D.	4,774,546
Eric L. Sorkin	4,762,046
Cecilia Chan	4,774,546
Frederick W. Wackerle	4,760,277

	VOTES FOR	VOTES AGAINST
Proposal 1 - Amendment to 2000 Stock Incentive Plan	1,654,160 (85.5%)	239,957 (12.38%)
Proposal 2 - Conversion of Series A Stock	1,838,179 (94.84%)	71,680 (3.70%)
Proposal 3 - Ratification of Deloitte & Touche LLP as independent auditors	4,675,879 (96.95%)	145,266 (3.01%)

23

Item 5. Other Information.

None.

Item 6. Exhibits, and Reports on Form 8-K.

1. Exhibits.

See Exhibit Index, page 25.

2. Reports on Form 8-K.

The Company filed a Current Report on Form 8-K on January 14, 2003 reporting the consummation of a joint venture whereby the Company purchased an 80% interest in a Hong Kong entity, Lenton Fibre Optics Development Limited, that owns commercial real estate in a "free trade zone" located in the Peoples Republic of China. The joint venture entity intends to construct a pharmaceutical manufacturing facility on the PRC property to be used to manufacture the Company's future products.

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

A Current Report on Form 8-K was filed on January 23, 2003 reporting the receipt of a \$2.1 million payment relating to the clinical research subcontract agreement between the Company and UNC funded by a grant from The Bill and Melinda Gates Foundation.

24

Exhibit Index

99.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

25

SIGNATURES

Pursuant to the requirements of Sections 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

IMMTECH INTERNATIONAL, INC.

Date: February 14, 2003

By: /s/ T. Stephen Thompson

T. Stephen Thompson
President and Chief Executive
Officer

Date: February 14, 2003

By: /s/ Gary C. Parks

Gary C. Parks
Treasurer, Secretary and Chief
Financial Officer
(Principal Financial and
Accounting Officer)

CERTIFICATIONS

I, T. Stephen Thompson, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Immtech International, Inc.:
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:
 - (a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - (b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - (c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - (a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officer and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: February 14, 2003

/s/ T. Stephen Thompson

T. Stephen Thompson
President & Chief Executive Officer

I, Gary C. Parks, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Immtech International, Inc.:

Edgar Filing: IMMTECH INTERNATIONAL INC - Form 10-Q

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

(a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

(b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

(c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officer and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: February 14, 2003

/s/ Gary C. Parks

Gary C. Parks
Chief Financial Officer